Gross Profit Margin (Quarterly) Chart

View Gross Profit Margin (Quarterly) for PTN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Gross Profit Margin (Quarterly) Chart
Start Trial

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
March 31, 2026 99.57%
December 31, 2025 87.59%
September 30, 2025 0.00%
June 30, 2025
March 31, 2025
December 31, 2024
September 30, 2024
June 30, 2024 51.46%
March 31, 2024
December 31, 2023 86.83%
September 30, 2023 91.65%
June 30, 2023 84.26%
March 31, 2023 74.79%
December 31, 2022 90.38%
September 30, 2022 72.65%
June 30, 2022 71.40%
March 31, 2022 16.57%
December 31, 2021 55.04%
September 30, 2021 0.94%
June 30, 2021 19.75%
March 31, 2021 -78.35%
December 31, 2020
September 30, 2020
June 30, 2020
March 31, 2020
Date Value
December 31, 2019 0.00%
September 30, 2019 0.00%
June 30, 2019 0.00%
March 31, 2019
December 31, 2018
September 30, 2018 0.00%
June 30, 2018 0.00%
March 31, 2018 0.00%
December 31, 2017 0.00%
September 30, 2017 0.00%
June 30, 2017 0.00%
March 31, 2017 0.00%
December 31, 2016
September 30, 2016
June 30, 2016
March 31, 2016
December 31, 2015
September 30, 2015
June 30, 2015
March 31, 2015
December 31, 2014 0.00%
September 30, 2014 0.00%
June 30, 2014
March 31, 2014
December 31, 2013

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Decoy Therapeutics, Inc. 94.02%
ACADIA Pharmaceuticals, Inc. 90.81%
Alnylam Pharmaceuticals, Inc. 76.88%
Anika Therapeutics, Inc. 65.15%
Savara, Inc. --

Gross Profit Margin (Quarterly) Related Metrics